Home

overview

In this interactive webinar, Dr Bertrand Tombal and Dr Pedro Barata will look at the standard of care for patients with early metastatic castration-resistant prostate cancer (mCRPC) and current unmet needs. They will go on to examine the latest data on new and emerging treatments such as radioligand therapies (RLTs) and RLT-inclusive combination therapies, and discuss the significance of these data for clinical considerations such as initial treatment selection and sequencing. The webinar will conclude with a question-and-answer session between faculty and attendees.

faculty

Moderator

Bertrand Tombal, MD, PhD

Chairman

Department of Surgery

Professor of Urology

Université Catholique de Louvain

Cliniques Universitaires Saint-Luc

Brussels, Belgium

Panelist

Pedro Barata, MD, MSc, FACP

Miggo Family Chair in Cancer Research

Director of Clinical GU Medical Oncology Research Program

University Hospitals Seidman Cancer Center

Associate Professor of Medicine

Case Western University

Cleveland, Ohio, United States

AGENDA

1:00 PM TZ

Welcome and Introduction

John Doe, MD

1:30 PM TZ

Introduction Medical Term

Lynn Doe, MD

2:00 PM TZ

Management of Acute Leukemia for the Community Healthcare Team

Jane Doe, MD

2:30 PM TZ

Panel Discussion

Kelly Doe, MD

5:00 PM TZ

Audience Q&A

TARGET AUDIENCE

This educational activity is intended for an audience of hematologists/oncologists, radiologists, and urologists.

GOAL STATEMENT

The goal of this activity is for learners to be better able to integrate the latest clinical developments into practice and provide appropriate care to patients with mCRPC.

LEARNING OBJECTIVES

Upon completion of this activity, participants will: Have increased knowledge regarding the [LIST] [ITEM]Latest clinical trial data of novel treatment strategies for early mCRPC[/LIST] [break] Have greater competence related to [LIST] [ITEM]Selecting the most optimal treatment regimen for those patients with mCRPC in the early setting [ITEM]Managing patients with mCRPC while on treatment [/LIST] [break] Demonstrate greater confidence in their ability to [LIST] [ITEM]Work efficiently in the multidisciplinary team to identify patients with mCRPC who may benefit from novel and emerging therapies[/LIST]

ACCREDITATION STATEMENT

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

[bold]For Physicians[/bold] [break] Medscape, LLC designates this live activity for a maximum of 0.5 [italic] AMA PRA Category 1 Credits™ [/italic] . Physicians should claim only the credit commensurate with the extent of their participation in the activity. [break] [bold]For Nurses[/bold] [break] Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs. [break] [bold]For Pharmacists[/bold] [break] Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-25-053-L01-P).

A Journal Club Session CME/CNE/CPE